A Bioequivalence Study of Two Loperamide Formulations in Healthy Volunteers

The primary objective of this study is to evaluate the **bioequivalence** of two formulations of **loperamide** in healthy volunteers. Bioequivalence studies are crucial in determining whether different formulations of a drug release the active ingredient into the bloodstream at the same rate and extent, ensuring therapeutic equivalence. This is clinically relevant as it ensures that patients receive the same therapeutic benefits and safety profile from different formulations of the same medication.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range of the participants is categorized under code "3," which typically includes adults. The trial population selection criteria and the total number of participants have not been disclosed by the sponsor. Participants are expected to be in good general health, as indicated by their classification as healthy volunteers. The study does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The trial includes a vulnerable population, although specific details regarding this aspect are not provided. Key inclusion or exclusion criteria have not been detailed by the sponsor.

The clinical trial is designed to evaluate the **bioequivalence** of two formulations of loperamide in **healthy volunteers**. This study is structured as a Phase 2, randomized, double-blind, controlled trial. The trial is expected to commence recruitment on July 10, 2025, and conclude by August 26, 2025. Participants will be involved in the study for a duration that aligns with the trial's timeline, with specific involvement periods determined by the study protocol.

The sequence of study visits begins with an inclusion visit, where potential participants undergo a screening process to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive one of the two formulations. Throughout the trial, follow-up visits will be scheduled to monitor the participants' health status, adherence to the study protocol, and any adverse events. These visits are crucial for ensuring the safety and well-being of the participants while collecting data necessary for the trial's objectives.

The end-of-study visit marks the conclusion of a participant's involvement in the trial. During this visit, final assessments are conducted to gather comprehensive data on the outcomes of the intervention. Participants may be withdrawn from the study prior to its completion if they experience significant adverse effects, fail to comply with the study protocol, or choose to withdraw consent. The trial's design and procedures are meticulously planned to ensure the integrity of the data collected and the safety of all participants involved.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be provided.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included in the provided data. As such, these aspects cannot be detailed in the current context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 2 study, indicating its focus on evaluating the efficacy and side effects of the intervention. The trial is scheduled to commence recruitment on July 10, 2025, with an estimated completion date of August 26, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, Phase 2 trials typically involve the use of validated scales, laboratory tests, or patient-reported outcomes to measure efficacy. The data collection and analysis will be conducted in accordance with standard clinical trial protocols, ensuring the reliability and validity of the results. The trial's design and execution will adhere to regulatory requirements and ethical standards to ensure the integrity of the efficacy assessment.